- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01112553
Treximet Migraine Brain Imaging Research Study (TREX)
October 30, 2012 updated by: David Borsook, MD, PhD, Mclean Hospital
Evaluation of Brain Activation in Complete Responders and Partial Responders Following Acute Administration of Treximet (Sumatriptan and Naproxen)
We are looking for volunteers who suffer from acute migraine (<14 episodes per month) to participate in a 2-visit brain imaging research study.
The goal of the study is to observe the effect of acute administration of Treximet during a migraine episode on the pain pathways of the migraine brain.
Visit 1 will consist of 1 hour, where participants will be signing the informed consent form, completing questionnaires, meeting with the study physician, and having QST (sensory testing to determine individual pain thresholds to a heat stimulus) performed.
Visit 2 will occur during a migraine episode.
Volunteers will be asked to contact the study team at the first onset of a migraine.
Upon arrival at Visit 2, individuals will be given an IV for blood draws.
Once these the IV is in place, subjects will enter the MRI and be asked to stay very still.
Scanning will occur for about 20 minutes, and then subjects will be given a Treximet tablet to combat their migraine.
More scanning will follow Treximet administration.
Some scans will have no stimulation, and others will apply a heat stimulus that subjects will rate using a pain scale.
Seven 5-mL blood samples will be drawn throughout the duration of the MRI session.
Both Visit 1 and Visit 2 will be compensated.
Study Overview
Status
Terminated
Conditions
Study Type
Observational
Enrollment (Actual)
2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Massachusetts
-
Belmont, Massachusetts, United States, 02478
- Neuroimaging Center, McLean Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
English-speaking males or females between the ages of 18 and 65, who suffer from acute migraine (<14 migraine episodes/ month), will be recruited for this study.
Description
Inclusion Criteria:
- Male or female (not pregnant or nursing)
- Age 18-65; with a focus on age 30-40 years
- Episodic migraine (experience migraine headache <14 days out of the month), with focus on left-sided pain
- Currently taking Treximet routinely for migraine treatment
- No significant medical history (No illnesses such as seizure disorder, diabetes, alcoholism, cardiac disease including coronary artery disease, psychiatric problems; drug addiction, respiratory problems, liver disease, etc.)
- No significant medication history, except for migraine
- Weight, <285 pounds
- Not claustrophobic
- No contraindication to taking triptans
Exclusion Criteria:
- Age <18 or > 65
- Significant medical problems (aside from pain before, during and after migraine episodes)
- Positive drug of abuse screen (excluding medications currently prescribed for their clinical condition, e.g. opioids, benzodiazepines, etc.)
- Use of opioid medications
- Claustrophobia
- History of dermatological hypersensitivity in the facial area
- Pregnancy
- Sensory loss detected on Quantitative Sensory Testing at screening
- Significant alcohol history (ingestion of 5 or more glasses (> 40 oz) of alcohol per week)
- Metal implants of any type (including dental bridges, crowns, retainers, orthodontic devices e.g. braces, etc.)
- Tattoos containing metallic ink on the neck, shoulders, upper arm and head (which could become heated up in the scanner, and potentially cause blistering or burning)
- Cardiac pacemakers
- Aneurysm clips and other vascular stents, filters, clips or other devices
- Prosthetic heart valves
- Other prostheses
- Neuro-stimulator devices
- Implanted infusion pumps
- Cochlear (ear) implants
- Ocular (eye) implants or known metal fragments in eyes
- Exposure to shrapnel or metal filings (sheet metal workers, welders, and others)
- Other metallic surgical hardware in vital areas
- Any known allergic side effects to Treximet
- Use of any of the following medications:
- Monoamine Oxidase A- Inhibitors (Azilect, Eldepryl, Marplan, Nardil, Parnate, Zelapar)
- SSRI's: citalopram/ Celexa, Lepraxo, paroxetine/ Paxil, fluoxetine/ Prozac, Sarafem, Symbyax, Sertraline/ Zoloft, Fluvoxamine/ Luvox
- SNRI's: duloxetine/ Cymbalta, venlafaxine/ Effexor
- Triptans: sumatriptan/ Imitrex, naratriptan/ Amerge, zolmitriptan/ Zomig, rizatriptan/ Maxalt, eletriptan/ Relpax, almotriptan/ Axert
- Ergotamine type medicines: Bellergal, Cafergot, Ergomar, Wiraine, Migranal/ DHE45, Sansert
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
Treximet
All migraine subjects will receive Treximet during a migraine episode at Visit 2.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2010
Study Completion (Actual)
October 1, 2012
Study Registration Dates
First Submitted
April 27, 2010
First Submitted That Met QC Criteria
April 27, 2010
First Posted (Estimate)
April 28, 2010
Study Record Updates
Last Update Posted (Estimate)
November 1, 2012
Last Update Submitted That Met QC Criteria
October 30, 2012
Last Verified
October 1, 2012
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2009-P-002689
- 400483 (Other Grant/Funding Number: GlaxoSmithKline)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Migraine
-
Behar, Caren, M.D.UnknownMigraine | Migraine Disorders | Migraine Headache | Acute MigraineUnited States
-
PfizerBioshin (Shanghai) Consulting Services Co., LtdCompleted
-
PfizerCompletedAcute MigraineUnited States
-
Neurolief Ltd.CompletedAcute MigraineUnited States, Israel
-
IlDong Pharmaceutical Co LtdCompletedAcute MigraineKorea, Republic of
-
Chordate MedicalTerminated
-
Chordate MedicalTerminated
-
Organon and CoCompleted
-
Organon and CoCompleted
-
Lateral Pharma Pty LtdCompletedAcute MigraineAustralia